6.39
0.29 (4.67%)
| Previous Close | 6.10 |
| Open | 6.24 |
| Volume | 2,486,548 |
| Avg. Volume (3M) | 3,447,709 |
| Market Cap | 569,179,328 |
| Price / Sales | 8.81 |
| Price / Book | 1.15 |
| 52 Weeks Range | |
| Earnings Date | 14 Aug 2025 |
| Operating Margin (TTM) | -111.10% |
| Diluted EPS (TTM) | -2.21 |
| Quarterly Revenue Growth (YOY) | 479.00% |
| Total Debt/Equity (MRQ) | 14.50% |
| Current Ratio (MRQ) | 9.84 |
| Operating Cash Flow (TTM) | -142.46 M |
| Levered Free Cash Flow (TTM) | -64.11 M |
| Return on Assets (TTM) | -19.35% |
| Return on Equity (TTM) | -34.26% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Verve Therapeutics, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.88 |
|
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 5.19% |
| % Held by Institutions | 94.62% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Casdin Capital, Llc | 31 Mar 2025 | 3,995,571 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 39.00 (Canaccord Genuity, 510.81%) | Buy |
| Median | 25.00 (291.54%) | |
| Low | 24.00 (Guggenheim, 275.88%) | Buy |
| Average | 29.33 (359.36%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 4.69 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 15 Apr 2025 | 39.00 (510.81%) | Buy | 4.97 |
| Guggenheim | 15 Apr 2025 | 24.00 (275.88%) | Buy | 4.97 |
| HC Wainwright & Co. | 14 Apr 2025 | 25.00 (291.54%) | Buy | 4.12 |
| 25 Mar 2025 | 15.00 (134.93%) | Buy | 5.84 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |